Trading and Custodian Members of the Exchange are requested to refer to notice nos. 20190118-43 dated January 18, 2019 and 20200701-27 dated July 01, 2020, detailing Revised Guidelines for Bidding in Offer for Sale (OFS) Segment. The above guidelines were issued by the Exchange with reference to Securities and Exchange Board of India (SEBI) circular no. SEBI/HO/MRD/DOPI/CIR/P/2018/159 dated December 28, 2018 regarding “Review of Offer for Sale (OFS) of Shares through Stock Exchange Mechanism”.
All Market Participants are hereby informed that Dhanuka Laboratories Limited (“Seller”), one of the members of the promoter group of the Orchid Pharma Limited (“Orchid / Company”) proposes to sell in aggregate up to 32,80,115 (Thirty Two Lakh Eighty Thousand One Hundred and Fifteen) Equity Shares (“Sale Shares”) held by the Seller in the Company, representing 8.04% of the total issued and paid-up equity share capital of the Company (“Offer”) on June 24, 2021 (“T Day”) (for non-retail Investors only) (“Non Retail Investors”) and on June 25, 2021 (“T+1 Day”) (for retail investors as described herein below (“Retail Investors”) and for Non-Retail Investors who choose to carry forward their un-allocated bids from T Day). The Sale Shares are proposed to be sold through a separate, designated window of BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) (BSE and NSE are together referred to as the “Stock Exchanges”), in accordance with a) Comprehensive Guidelines on Offer for Sale of Shares by Promoters through Stock Exchange Mechanism’ issued by the Securities and Exchange Board of India (“SEBI”) vide its circular bearing no. CIR/MRD/DP/ 18 /2012 dated July 18, 2012, as amended by circulars bearing nos. CIR/MRD/DP/04/2013 dated January 25, 2013, CIR/MRD/DP/17/2013 dated May 30, 2013, CIR/MRD/DP/24/2014 dated August 8, 2014, CIR/MRD/DP/32/2014 dated December 1 2014, CIR/MRD/DP/12/2015 dated June 26, 2015, CIR/MRD/DP/36/2016 dated February 15, 2016, CIR/MRD/DP/65/2017 dated June 27, 2017 and SEBI/HO/MRD/DOPI/CIR/P/2018/159 dated December 28, 2018 (the “OFS Circular”), read together with Section 21 of Chapter I of the ‘Master Circular for Stock Exchange and Clearing Corporation’, issued by SEBI vide its circular bearing no. SEBI/HO/MRD/DP/CIR/P/117 dated October 25, 2019 (together referred to as “SEBI OFS Circulars”);b) The ‘Revised Guidelines for Bidding in Offer For Sale (OFS) Segment’ issued by the BSE, vide its circular bearing no. 20200701-27 dated July 1, 2020 and “OFS Segment- Placing of price bids by Retail Investors (on T+1 Day) below Cut-off Price Not Allowed” issued by the BSE vide its circular bearing no. 20210322-21 dated March 22, 2021, and to the extent applicable, the previous notices issued by BSE in this regard; and c) The ‘Offer for Sale-Introduction of Interoperability’ issued by NSE vide its circular bearing no. 51/2020 dated June 30, 2020, and “Offer for Sale – Retail category price bids below cut-off not allowed in RS series on T+1 day” issued by NSE vide its circular bearing no. 32/2021 dated March 22, 2021, and to the extent applicable, the previous notices issued by NSE in this regard.
The particulars of the above offer for sale are attached to this notice.
The floor price of the Offer shall be Rs. 375 (Rupees Three Hundred & Seventy Five) per Equity Share of the Company.
Market participants are further requested to note that the Exchange would disseminate the details of this Offer for Sale on BSE Website – www.bseindia.com.
Atul Dhotre
Senior Manager
Listing Sales & Ops
June 23, 2021 |